NEW YORK, NY / ACCESSWIRE / May 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Plug Power Inc. (NASDAQ:PLUG)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/plug-power-inc-loss-submission-form?prid=15441&wire=1
Lead Plaintiff Deadline: May 7, 2021
Class Period: November 9, 2020 - March 1, 2021
Allegations against PLUG include that: (1) the Company would be unable to timely file its 2020 annual report due to delays related to the review of classification of certain costs and the recoverability of the right to use assets with certain leases; (2) the Company was reasonably likely to report material weaknesses in its internal control over financial reporting; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Amdocs Limited (NASDAQ:DOX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/amdocs-limited-loss-submission-form?prid=15441&wire=1
Lead Plaintiff Deadline: June 8, 2021
Class Period: December 13, 2016 - March 30, 2021
Allegations against DOX include that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15441&wire=1
Lead Plaintiff Deadline: June 18, 2021
Class Period: June 15, 2020 - April 4, 2021
Allegations against ACAD include that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong